药物临床试验药物管理员核心能力评价指标体系构建及应用OA
Construction and Application of a Core Competency Assessment Index System for Drug Administrators in Drug Clinical Trials
目的 构建适用于我国药物临床试验药物管理员(以下简称药物管理员)的核心能力评价指标体系,并评价药物管理员的核心能力.方法 通过文献研究法、专家咨询法,从药物管理员的角色定位、岗位职责和工作范围出发,初步构建核心能力评价指标体系,并采用德尔菲法对指标体系进行修改和验证.依据构建的评价指标体系对 38 家药物临床试验机构的药物管理员开展电子问卷调查.采用Wilcoxon符号秩和检验比较药物管理员在各核心能力指标的重要性评分和自我能力评分.结果 共 19 名专家完成 2 轮德尔菲法专家函询,专家积极系数分别为 100.00%和 95.00%,专家权威系数为 0.929,专家Kendall's W协调系数分别为 0.236 和 0.278(均P<0.001).药物管理员核心能力评价指标体系包括一级指标 3项,二级指标 35项.共向 38家药物临床试验机构发放问卷 95份,回收有效问卷 95 份,有效回收率为 100.00%.在个人专业能力维度,9 个指标中有 2 个指标显示自我能力评分与重要性评分间存在显著差异(P<0.05);在药物管理能力维度,21 个指标中有 3 个指标存在显著差异(P<0.05);在质量控制能力维度,5 个指标中有 1 个指标存在显著差异(P<0.05).结论 采用德尔菲法构建的药物管理员核心能力评价指标体系可为药物管理员的核心能力评价提供客观、可量化的依据,并可为构建规范化的药物管理员教育培训体系提供参考.
Objective To construct a core competency assessment index system for drug administrators in drug clinical trials(hereinafter referred to as drug administrators)in China,and to evaluate the core competencies of drug administrators.Methods A preliminary core competency assessment index system was constructed through literature research and expert consultation methods from the perspectives of the role positioning,job responsibilities,and work scope of drug administrators,and the index system was modified and validated by the Delphi method.Based on the constructed assessment index system,an electronic questionnaire survey was conducted among drug administrators from 38 drug clinical trial institutions.Wilcoxon signed-rank test was used to compare the role-importance and self-competence scores scores of drug administrators in various indexes of core competencies.Results A total of 19 experts completed two rounds of Delphi expert inquiry,with expert positivity coefficients of 100.00%and 95.00%,expert authority coefficient of 0.929,and expert Kendall's W coordination coefficients of 0.236 and 0.278,respectively(all P<0.001).The core competency assessment index system of drug administrators consisted of three first-level indicators and thirty-five second-level indicators.A total of 95 questionnaires were distributed to 38 drug clinical trial institutions,and 95 valid questionnaires were collected,with an effective response rate of 100.00%.In the dimension of individual professional competency,two out of nine indicators showed a significant difference between self-competence score and role-importance score(P<0.05).In the dimension of drug management competency,three out of tweenty-one indicators showed a significant difference(P<0.05).In the dimension of quality control competency,one of five indicators showed a significant difference(P<0.05).Conclusion The core competency assessment index system of drug administrators constructed by the Delphi method can provide an objective and quantifiable basis for the assessment of drug administrators'core competencies,and can also provide a reference for the construction of a standardized drug administrator education and training system.
尹园园;蒋清青;汤晓华;毛巍然;陈霞
重庆大学附属肿瘤医院临床研究中心·重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室,重庆 400030重庆大学附属肿瘤医院临床研究中心·重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室,重庆 400030重庆大学附属肿瘤医院临床研究中心·重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室,重庆 400030重庆大学附属肿瘤医院临床研究中心·重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室,重庆 400030重庆大学附属肿瘤医院临床研究中心·重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室,重庆 400030
医药卫生
药物临床试验药物管理员核心能力评价指标体系德尔菲法
drug clinical trialsdrug administratorcore competenciesassessment index systemDelphi method
《中国药业》 2026 (7)
29-34,6
重庆市技术预见与制度创新项目[CSTB2023TFII-OIX0002].
评论